Vladimir Putin calls for boost in production of two Russian COVID-19 vaccines

Vlimir Putin ordered authorities to ramp up production of two Russian COVID-19 vaccines on Wednesday, October 14. According to reports, he also called for sufficient production to fill up Russian market first.

"We need to boost production of our first vaccine and second one, and, of course, we have to fill Russian market with this medication, first of all", said Russian President. Putin also congratulated Vektor research centre for its work on new COVID-19 vaccine, Russia's second vaccine against infection to be registered. 

RE: Armenia-Azerbaijan Conflict: Russia Urges Both Countries To Hor Ceasefire Agreement

Early clinical trials started

After anuncing world's first registered COVID-19 vaccine, Russia is reported to have begun early clinical trials for a second COVID-19 vaccine. According to vaccine developer, early clinical trials of a second Russian COVID-19 vaccine have proved successful. 

Earlier on October 1, Vektor, Russia's state virology research centre in Siberia, said that early-st trials were successful for its own experimental vaccine, named 'EpiVacCorona'. first two phases of clinical trials demonstrated effectiveness and safety of EpiVacCorona vaccine, Vektor's press department told a Russian news ncy. 

RE: Russia’s Soyuz Capsule Reaches ISS In Record Time, Astronauts Enter Station

post-registration clinical trials would begin with 5,000 volunteers in Siberia, Vektor said and ded that re would be a separate clinical trial involving 150 volunteers who are over 60 years of . Furr, lab will begin placebo-controlled trials on 5,000 Russian volunteers between s of 18 and 60.

Vektor furr said EpiVacCorona vaccine is a two-component vaccine, and interval between ministration of first and second components is 21 days. Russia plans to manufacture an initial 10,000 doses and production is expected to begin in vember, Vektor informed.

In August, Russia h anunced that it h developed world's first registered vaccine named Sputnik V. vaccine registration raised concerns among Western scientists as COVID-19 vaccine developed by Moscow's Gamaleya research centre h received approval before clinical trials h been completed.

RE: rway Holds Russia Responsible For Cyberattack On Parliament, Moscow Rejects Allegations

RE: US Calls Out China & Russia's Lobbying; Asks Think Tanks To Disclose Foreign Funding

(With ANI Inputs; Im Credits - AP)